Artemis Medicare Services Limited
Artemis Medicare Services Limited Fundamental Analysis
Artemis Medicare Services Limited (ARTEMISMED.NS) shows weak financial fundamentals with a PE ratio of 33.49, profit margin of 9.27%, and ROE of 11.49%. The company generates $11.8B in annual revenue with moderate year-over-year growth of 6.64%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 51.9/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze ARTEMISMED.NS's fundamental strength across five key dimensions:
Efficiency Score
WeakARTEMISMED.NS struggles to generate sufficient returns from assets.
Valuation Score
WeakARTEMISMED.NS trades at a premium to fair value.
Growth Score
ExcellentARTEMISMED.NS delivers strong and consistent growth momentum.
Financial Health Score
ExcellentARTEMISMED.NS maintains a strong and stable balance sheet.
Profitability Score
WeakARTEMISMED.NS struggles to sustain strong margins.
Key Financial Metrics
Is ARTEMISMED.NS Expensive or Cheap?
P/E Ratio
ARTEMISMED.NS trades at 33.49 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, ARTEMISMED.NS's PEG of 7.54 indicates potential overvaluation.
Price to Book
The market values Artemis Medicare Services Limited at 3.67 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 20.49 times EBITDA. This signals the market has high growth expectations.
How Well Does ARTEMISMED.NS Make Money?
Net Profit Margin
For every $100 in sales, Artemis Medicare Services Limited keeps $9.27 as profit after all expenses.
Operating Margin
Core operations generate 17.77 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $11.49 in profit for every $100 of shareholder equity.
ROA
Artemis Medicare Services Limited generates $6.77 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Artemis Medicare Services Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Artemis Medicare Services Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
ARTEMISMED.NS converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
33.49
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
7.54
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.67
vs 25 benchmark
P/S Ratio
Price to sales ratio
3.51
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.32
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.11
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.11
vs 25 benchmark
ROA
Return on assets percentage
0.07
vs 25 benchmark
ROCE
Return on capital employed
0.16
vs 25 benchmark
How ARTEMISMED.NS Stacks Against Its Sector Peers
| Metric | ARTEMISMED.NS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 33.49 | 29.45 | Worse (Expensive) |
| ROE | 11.49% | 779.00% | Weak |
| Net Margin | 9.27% | -24936.00% (disorted) | Weak |
| Debt/Equity | 0.32 | 0.26 | Weak (High Leverage) |
| Current Ratio | 2.11 | 4.65 | Strong Liquidity |
| ROA | 6.77% | -19344.00% (disorted) | Weak |
ARTEMISMED.NS outperforms its industry in 1 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Artemis Medicare Services Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
43.03%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
255.14%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
169.03%
Industry Style: Defensive, Growth, Innovation
High Growth